Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $38

Benzinga Newsdesk www.benzinga.com Positive 81.5%

Neg 0% Neu 0% Pos 81.5%

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $35 to $38.